FDA Focuses on Eczema

THE FACTS ON ECZEMA: The WALL STREET JOURNAL

  • Affects an estimated 7% to 10% of U.S. adults and 12% of children
  • Recent advances have identified molecules driving the disease with new treatments developing

Kelly Hayes of Chicago says she has benefited from the new drug dupilumab after years of suffering with eczema.

Kelly Hayes of Chicago says she has benefited from the new drug dupilumab after years of suffering with eczema. 

Click photo to be linked to The Wall Street Journal article

Comments: